CClinicalTrials.gg
CompletedNCT03671577Updated Jan 29, 2021

Building Closer Friendships in Social Anxiety Disorder

An interventional study of Building Closer Friendships in Social Anxiety, sponsored by Florida State University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-29.

Sponsored by Florida State University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study assesses whether a 4-week computerized intervention can be used to decrease fear of intimacy, and loneliness and improve perceived social support in people with Social Anxiety Disorder.

Read the detailed description

This study hopes to assess whether a month long computerized intervention aimed at giving people skills to form closer friendships. Participants will be randomized into an active treatment condition or a wait list control. We hypothesize that 1) participants in the treatment condition will have lower fear of intimacy at post treatment than those in the waitlist condition 2) participants in the treatment condition will have lower levels of loneliness than those in the waitlist condition 3) participants in the treatment condition will have higher perceived social support than those in the waitlist condition.

02

Conditions studied

  • Social Anxiety
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 55 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Florida State University is the lead sponsor of 241 studies on the registry; 46 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 9 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Social Anxiety Disorder Diagnosed by the Mini International Neuropsychiatric Interview
  • Social Phobia Inventory Score >19
  • Stable psychotropic medication for the past month and kept stable for duration of study

Exclusion criteria

Exclusion Criteria:

  • Currently participating in therapy
  • Current Substance Dependence
  • Bipolar Disorder or psychotic illness
  • Current suicidality (imminent risk)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Active Treatment

    four week computerized intervention designed to reduce fear of intimacy

    Behavioral: Building Closer Friendships

  • No intervention
    Wait List Control

    Participants will continue as usual and will be given the option to receive the active treatment after completion of the study

Interventions

  • BehavioralBuilding Closer Friendships

    Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships

06

What researchers measure

Primary outcomes

  1. Multidimensional Scale of Perceived Social Support

    Self-report scale that measures perceived levels of social support. Scores range from 12 to 84 with higher scores indicating higher levels of perceived social support. The three subscales (friends, family and significant other) all have a range of 4 to 28 with higher scores indicating higher levels of perceived social support.

    Time frame: Change in Perceived Social Support from baseline to post treatment (4weeks) and one month follow up (8 weeks)

  2. Fear of Intimacy Scale-friend version

    self report scale measuring fear of intimacy in friendships. Scores range from 26 to 130 with higher scores indicating a higher level of fear of intimacy.

    Time frame: Change in fear of intimacy from baseline to post treatment (4weeks) and one month follow up (8 weeks)

Secondary outcomes

  1. UCLA Loneliness Scale

    A 20 item Self report scale measuring loneliness. Scales range from 0 to 60 with higher scores indicating a higher level of loneliness.

    Time frame: Change in loneliness from baseline to post treatment (4weeks) and one month follow up (8 weeks)

  2. Social Phobia inventory

    Self-report scale that measures Social anxiety symptoms. Scores range from 0 to 68 with higher scores indicating higher levels of social anxiety symptoms.

    Time frame: Change in social anxiety symptoms from baseline to post treatment (4 weeks) and one month follow up (8 weeks)

  3. State-Trait Inventory for Cognitive and Somatic Anxiety-Trait Version (STICSA-T)

    Self-report measure used to assess overall anxiety symptoms. Scores range from 21 to 84 with higher scores indicating higher levels of overall anxiety.

    Time frame: Change in overall anxiety symptoms from baseline to post treatment (4 weeks) and one month follow up (8 weeks)

  4. Center for Epidemiological Studies Depression Scale (CES-D)

    Self-report measure used to assess depressive symptoms. Total scores range from 0 to 60 with higher scores indicating a higher level of depressive symptoms.

    Time frame: Change in depression symptoms from baseline to post treatment (4 weeks) and one month follow up (8 weeks)

  5. Interpersonal Needs Questionnaire (INQ)

    Self report measure of suicide vulnerability. Total scores range from 15 to 105, with higher scores indicating a higher vulnerability for suicide.

    Time frame: Change in suicide vulnerability from baseline to post treatment (4 weeks) and one month follow up (8 weeks)

07

Study locations

1 site
  • Florida State University
    Tallahassee, Florida 32304, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03671577
Lead sponsor
Florida State University
Responsible party
Jesse Cougle (Associate Professor, Florida State University) — Principal investigator
First posted
Sep 14, 2018
Start date
Oct 25, 2018
Primary completion
Dec 15, 2019
Completion
Dec 15, 2019
Last update
Jan 29, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion